Novel targeted therapies and immunotherapy for advanced thyroid cancers
The FDA has approved four different drugs targeting the Mitogen-Activated Protein Kinase (MAPK) signaling pathway in the treatment of advanced thyroid cancers.
The claim highlights the current FDA‑approved targeted therapeutic options for advanced thyroid cancers, underscoring the availability of actionable drugs and the opportunity to build on these treatments to improve patient outcomes.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management